The Best of ASCO® 2026 in Qatar aims to provide participants with the latest expert consensus and research findings on the treatment and management of both common and rare cancers in Qatar.
The conference objectives are as follows:
- Enable Hamad Medical Corporation cancer professionals to identify and critically evaluate the latest research on common cancers, such as breast, colorectal, lung, and prostate, and assess their implications for clinical practice and treatment options.
- Identify and evaluate emerging evidence in the care and management of rare cancers, including neurological, head and neck, urological, gynecological, and sarcomas, to inform practice and improve patient outcomes.
- Assess the implications of advances in emerging therapeutics, such as immunotherapy, molecular precision medicine, and tumor biology, for cancer practice and research at HMC.
- Explore the latest approaches in symptom management and survivorship to support the development and enhancement of cancer services at HMC.
